Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Japan.
Department of Respiratory Medicine, National Hospital Organization Fukuokahigashi Medical Center, Japan.
Intern Med. 2024 May 15;63(10):1459-1463. doi: 10.2169/internalmedicine.3096-23. Epub 2024 Mar 4.
We present the case of a 61-year-old man who developed coronavirus disease 2019 (COVID-19) and died during treatment for relapsing polychondritis. The patient was intubated and treated with steroid pulse therapy, remdecivir, antibacterial agents, baricitinib, and tocilizumab. However, his respiratory condition worsened, and he died 108 days after disease onset. An autopsy revealed diffuse alveolar damage in the fibrotic phase in all lung lobes, diffuse pulmonary ossification, and cytomegalovirus-infected cells in the middle lobe of the right lung. We herein discuss the clinical features and pathological findings of COVID-19 in immunosuppressed patients.
我们报告了 1 例 61 岁男性 COVID-19 患者,该患者在治疗复发性多软骨炎时死亡。患者接受了气管插管和类固醇脉冲治疗、瑞德西韦、抗菌药物、巴瑞替尼和托珠单抗治疗。然而,他的呼吸状况恶化,发病后 108 天死亡。尸检显示所有肺叶均存在纤维化期弥漫性肺泡损伤、弥漫性肺骨化和右肺中叶巨细胞病毒感染细胞。本文讨论了免疫抑制患者 COVID-19 的临床特征和病理发现。
Intern Med. 2024-5-15
Am J Clin Pathol. 2020-5-5
Ugeskr Laeger. 2020-7-6
Am J Clin Pathol. 2020-9-8
Rev Soc Bras Med Trop. 2022-3-14
Radiol Cardiothorac Imaging. 2021-4-1
Mod Pathol. 2020-6-19
JAMA. 2020-6-23
N Engl J Med. 2020-2-28